PQQ (Pyrroloquinoline Quinone)
CofactorPreclinicalAlso known as: PQQ, Pyrroloquinoline quinone, Methoxatin, PQQ disodium salt, Pyrroloquinoline quinone disodium, BioPQQ, MGCPQQ, PureQQ, 4,5-dihydro-4,5-dioxo-1H-pyrrolo[2,3-f]quinoline-2,7,9-tricarboxylic acid, PQQH2, PQQ hydroquinone, Reduced PQQ, Coenzyme PQQ, Quinone cofactor, o-Quinone cofactor
Pyrroloquinoline quinone (PQQ, methoxatin) is a small tricyclic o-quinone originally discovered in 1964 as the prosthetic group of bacterial methanol dehydrogenase. In methylotrophic and methanotrophic bacteria (organisms that live on methane or methanol), PQQ serves as a redox cofactor for several quinoprotein dehydrogenases — methanol dehydrogenase, glucose dehydrogenase, ethanol dehydrogenase — catalyzing two-electron oxidations of alcohols, aldehydes, and sugars via stable semiquinone intermediates.
Overview
At A Glance
PQQ's mechanism of action in mammalian biology is dominated by three proposed modes: (1) as a redox-active antioxidant/pro-oxidant modulator with exceptional catalytic stability, (2) as an activator of mitochondrial biogenesis via the PGC-1α/NRF1/NRF2/TFAM transcriptional axis, a…
Overview
Pyrroloquinoline quinone (PQQ, methoxatin) is a small tricyclic o-quinone originally discovered in 1964 as the prosthetic group of bacterial methanol dehydrogenase. In methylotrophic and methanotrophic bacteria (organisms that live on methane or methanol), PQQ serves as a redox cofactor for several quinoprotein dehydrogenases — methanol dehydrogenase, glucose dehydrogenase, ethanol dehydrogenase — catalyzing two-electron oxidations of alcohols, aldehydes, and sugars via stable semiquinone intermediates. PQQ is an ancient cofactor, chemically simpler than NAD+ or FAD, and its discovery sparked decades of interest in whether PQQ plays a comparable role in mammalian biology. The answer has been contested and remains incompletely resolved: PQQ is present in mammalian tissues at low concentrations, is found in a wide range of foods (fermented soy, parsley, green tea, kiwi, papaya, breast milk), produces measurable deficiency syndromes in strict PQQ-restricted animal diets, and has been proposed as a novel B vitamin — yet no mammalian apo-enzyme requiring PQQ as a prosthetic group has been definitively characterized, and PQQ's essentiality in humans is not accepted by the IOM or EFSA. This creates a regulatory and scientific ambiguity similar to boron's — PQQ may have biological activity in mammals, but it does not meet formal essentiality criteria, and the evidence for supplementation benefit in healthy humans is mechanistically suggestive but clinically limited.
The chemistry of PQQ is distinctive and underlies much of its proposed biological activity. The tricyclic aromatic structure contains an ortho-quinone (adjacent carbonyl groups) that can accept electrons to form a semiquinone radical intermediate and then a fully reduced hydroquinone (PQQH2). Unlike many quinones, PQQ undergoes this redox cycling with exceptional catalytic efficiency — a single PQQ molecule can go through an estimated 20,000-100,000 redox cycles before degradation, compared to approximately 4 cycles for vitamin C or 100-200 for other polyphenols before oxidative destruction. This redox stability is the foundation of PQQ's proposed antioxidant role. Additionally, the ortho-quinone chemistry enables PQQ to react with amino groups on amino acids and proteins, forming quinoprotein adducts — a mechanism relevant to the bacterial quinoprotein enzymes and potentially to mammalian signaling. The three carboxylic acid groups make PQQ water-soluble, ionized at physiologic pH, and well-suited for renal excretion.
PQQ was proposed as a novel B vitamin in a 2003 Nature paper (Kasahara 2003) based on studies of mice fed PQQ-deficient diets and analysis of the aminoadipic semialdehyde dehydrogenase (AASDH) enzyme system. The claim was that PQQ was an essential dietary factor required for AASDH activity. Subsequent critical reevaluation and the authors' own follow-up work determined that AASDH does not use PQQ as a cofactor in mammals, and the claim of PQQ being a new B vitamin was not validated. However, PQQ-deficient diets in mice do reliably produce a reproducible syndrome — growth impairment, reproductive failure, skin fragility, impaired neonatal survival — first described by Killgore, Smidt, Steinberg 1989 and refined by subsequent work (Stites 2000; Rucker 2009). This syndrome is ameliorated by dietary PQQ supplementation. Whether this represents true essentiality (deficiency syndrome as with a vitamin) or a pharmacologic effect of a biologically active dietary compound remains debated. The phenotype is subtle enough that formal nutritional essentiality has not been declared, but PQQ is not a trivial dietary factor either.
PQQ is widely distributed in foods, though typically at low concentrations. The highest documented food concentrations are in fermented soybeans (natto) at approximately 61 ng/g, parsley at 34 ng/g, green tea at 30 ng/g, kiwi at 27 ng/g, papaya at 27 ng/g, spinach at 22 ng/g, tofu at 24 ng/g, dark chocolate at 9 ng/g, and human breast milk at approximately 140-180 ng/mL (substantially more concentrated than cow's milk at 4-17 ng/mL, suggesting physiologic concentration into breast milk). The presence in breast milk at meaningful concentrations is one argument for PQQ being a biologically important dietary factor. Typical Western dietary intake is estimated at 0.1-1 mg/day, though accurate intake data are limited because few food composition databases include PQQ.
The supplementation dose range (10-40 mg/day) is approximately 10-400 times typical dietary intake, placing supplementation firmly in the pharmacologic rather than nutritional replacement range. This is similar to the situation for many polyphenols and flavonoids — dietary exposure is modest, supplementation achieves levels that may produce measurable biological effects, but the relationship to dietary deficiency is indirect. At supplementation doses, PQQ is absorbed with moderate efficiency (estimated 20-40%), circulates briefly in plasma, distributes to tissues (with notable concentration in kidney, liver, heart, and brain), and is excreted via urine predominantly as intact PQQ or PQQ conjugates.
The most commercially relevant application of PQQ supplementation is mitochondrial biogenesis. Chowanadisai 2010 J Biol Chem demonstrated in mouse and human cell culture that PQQ at physiologic and supraphysiologic concentrations activates the PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) pathway, the master regulator of mitochondrial biogenesis. PGC-1α activation produces increased mitochondrial DNA content, increased expression of mitochondrial proteins (NRF1, NRF2, TFAM), and functionally increased cellular respiratory capacity. This mechanism underlies the marketing claim that PQQ produces "new mitochondria" — an oversimplification of a real mechanism. Whether PGC-1α activation in isolated cell culture translates to measurable mitochondrial expansion in human tissue during supplementation is an open question; human studies of mitochondrial biomarkers with PQQ are limited.
The second major supplementation claim is cognitive/memory enhancement. Nakano 2012 Functional Foods in Health and Disease trial in 41 middle-aged and elderly Japanese subjects supplemented with 20 mg PQQ/day for 12 weeks showed improvements in a cognitive battery (particularly in subjects with lower baseline cognitive function). Nakano 2009 had shown similar effects in a smaller pilot. Itoh 2016 examined sleep and stress and found modest improvements in sleep quality and stress markers. These are small Japanese trials, not replicated in large Western populations. The mechanism is proposed to involve mitochondrial function, NGF (nerve growth factor) stimulation, and antioxidant effects on neural tissue.
The third area of supplementation claim is cardiovascular — antioxidant protection, improved LDL oxidation resistance, and in pre-clinical models, protection against ischemia-reperfusion injury (Tao 2007 showed PQQ protection of rat hearts in I/R model). No large human cardiovascular outcome trial has been conducted.
BodyHackGuide's take: PQQ is mechanistically interesting and biologically plausible, with a wide safety margin and low toxicity. The mitochondrial biogenesis mechanism is supported by good cell biology data. The human clinical data, however, are limited — a handful of small Japanese trials mostly in cognitive outcomes, limited Western replication, and no large endpoint trials. At 10-20 mg/day (the typical supplementation dose, as BioPQQ disodium salt or equivalent), PQQ is safe, the theoretical mechanism is sound, and modest benefits on cognition and energy have been reported by some users. Whether this translates to meaningful health improvement for the typical user is uncertain. PQQ is a reasonable addition to a mitochondrial-support stack (with CoQ10, alpha-lipoic acid, creatine, exercise) but it is not a foundational intervention. The cost is moderate ($30-60/month at typical doses), making it one of the more expensive trace cofactors to supplement. For users interested in the mitochondrial biogenesis angle, PQQ 10-20 mg/day for 3-6 months as a trial, alongside the foundational mitochondrial stack, is a defensible approach. For users without specific mitochondrial or cognitive concerns, PQQ is probably not a high-priority supplement.
Chemical Information
IUPAC Name
Not yet available
CAS Number
Not yet available
Molecular Formula
Not yet available
Molecular Mass
Not yet available
Chemical data is being compiled for this compound.
Dosing & Protocols
Unlock Dosing Protocols
Free account gets you:
- View beginner, intermediate & advanced protocols
- See weight-based dosing calculations
- Access cycle length & frequency data
2,800+ researchers already in
Research
Unlock Research Data
Free account gets you:
- Browse PubMed study summaries
- See clinical trial phases & results
- Access mechanism of action details
2,800+ researchers already in
Interactions
Contraindications
Absolute contraindications:
- Known hypersensitivity to PQQ or PQQ-containing products.
Relative contraindications (caution or specialist guidance):
- Pregnancy: No adequate human data. Standalone supplementation not recommended.
- Lactation: No adequate human data. Standalone supplementation not recommended.
- Children: Not recommended outside research contexts.
- Advanced kidney disease (CKD stage 4-5, dialysis): Accumulation risk due to renal excretion dependence. Avoid or use only under specialist guidance.
- Active cancer treatment: No data on PQQ in oncology settings. Consult oncology team.
- Active neurodegenerative disease: PQQ is not a therapy. Standard medical management is primary.
- Anticoagulation with warfarin: Theoretical concern (quinone structure). Monitor INR if combining.
- Autoimmune disease: PQQ's immunomodulatory effects are not well studied. Caution.
- Specific mitochondrial disorders (primary mitochondrial disease): Specialist evaluation required before supplementation.
Drug interactions (theoretical/speculative):
- Proteasome inhibitors, other quinone-containing drugs: no established interactions; consider total quinone exposure.
- Metformin, GLP-1 agonists: theoretically complementary mitochondrial effects; no interaction concerns.
- Statins: theoretically complementary (statins may reduce CoQ10; PQQ supports mitochondrial biogenesis). No interaction.
Populations where supplementation is of unclear value:
- Young healthy adults without specific fatigue or cognitive concerns.
- Individuals with established medical conditions who have not first addressed foundational management.
- Users with limited supplementation budget for whom lower-cost interventions would be higher yield (foundational vitamins, minerals, fish oil, creatine).
Situations warranting discontinuation:
- Persistent headache not relieved by dose reduction.
- Sleep disturbance not relieved by timing change.
- Skin rash or hypersensitivity.
- Gastrointestinal intolerance.
- No subjective benefit after 12-week trial.
Quality concerns:
- Avoid PQQ products without third-party testing or certificate of analysis.
- Avoid ultra-inexpensive PQQ (likely substandard or mislabeled).
- Verify BioPQQ or MGCPQQ designation for assurance of authentic content.
Long-term considerations:
- Long-term (over 1 year) safety data in humans are limited. Favorable short-term tolerability suggests no major concerns, but users should be aware of this evidence gap.
- Annual reassessment of whether continued supplementation is subjectively beneficial is reasonable.
Special considerations:
- Users on multiple redox-active supplements (vitamin E, CoQ10, astaxanthin, R-lipoic acid, etc.) may have complex redox interactions. Stack with integrative health professional guidance if pursuing extensive antioxidant protocols.
- Athletes should be aware that while PQQ is generally permitted by anti-doping regulations, product quality variations mean some products may contain unlisted substances. Use WADA-compliant products if competing.
Research Disclaimer
This interaction data is compiled from published research and community reports. It may not be exhaustive. Always consult a healthcare professional before combining compounds.
No listings found for PQQ (Pyrroloquinoline Quinone).
Research Score
1520 PubMed studies
Quality Indicators
Data Completeness
63%Research Credibility
Well-researched compound
Quick Facts
Trial Phase
Preclinical
Research Disclaimer
This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.
Frequently Asked Questions
Is PQQ an essential vitamin?
PQQ has been proposed as a novel B vitamin but has not been formally classified as essential by the IOM, EFSA, or WHO. The 2003 Kasahara Nature paper (PMID 12679798) claimed PQQ was an essential B vitamin, but subsequent analysis determined the specific enzymatic target proposed (AASDH) does not use PQQ as a cofactor in mammals. PQQ-deficient diets in mice produce a reproducible syndrome (growth impairment, reproductive failure, skin fragility; Stites 2000 PMID 10888956), suggesting biological importance, but no mammalian enzyme has been definitively shown to require PQQ as a prosthetic group. PQQ is best described as a biologically active dietary compound with possible nutritional relevance, not a confirmed vitamin.
What is the mechanism of PQQ for mitochondrial biogenesis?
Chowanadisai 2010 J Biol Chem PMID 20022988 demonstrated that PQQ activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) in cell culture at physiologic concentrations. PGC-1α is the master regulator of mitochondrial biogenesis, coordinating expression of mitochondrial proteins via NRF1/NRF2 and mitochondrial DNA replication via TFAM. Activation of this axis produces increased mitochondrial number per cell, improved respiratory capacity, and improved metabolic flexibility. The upstream mechanism involves CREB phosphorylation (cAMP response element binding protein). Whether cell culture effects translate to measurable mitochondrial expansion in human tissue during supplementation has not been definitively demonstrated in biopsy studies, but indirect markers (energy, cognition) have shown some positive signals.
What dose of PQQ is effective?
Human trials have predominantly used 20 mg/day, and this is the dose with best supportive evidence (Nakano 2012 for cognitive effects, Itoh 2016 for sleep and stress). Some users report benefits at 10 mg/day. Doses above 20 mg/day have not been shown in human trials to produce additional benefit, and may increase side effect risk. BodyHackGuide recommends starting at 10 mg/day for 2 weeks, then increasing to 20 mg/day if tolerated and seeking greater effect. The dose-response curve appears to plateau in the 10-20 mg range. Doses above 30-40 mg/day are not evidence-supported.
Can PQQ improve cognitive function?
Nakano 2012 examined 41 middle-aged and elderly Japanese subjects given 20 mg PQQ/day for 12 weeks, showing improvements in memory and attention domains, particularly in subjects with lower baseline cognitive function. Itoh 2016 PMID 26857805 showed modest cognitive and sleep quality improvements at 20 mg/day. These trials are small (under 50 subjects), short-duration (8-12 weeks), and predominantly Japanese. Replication in large Western populations has not occurred. The mechanism involves mitochondrial support in brain tissue, NGF stimulation, and modest antioxidant effects. Expect modest benefits if any; PQQ is not a dramatic cognitive enhancer and not a treatment for established dementia.
Is PQQ safe?
At supplementation doses (10-20 mg/day), PQQ is well-tolerated in available human trials with minimal adverse effects. Intermediate-duration trials (12 weeks) have shown no clinically significant laboratory or adverse events. Post-marketing surveillance in Japan (where BioPQQ has been sold since 2004) has not revealed safety concerns. Headache is the most common side effect at higher doses (above 30 mg/day). Long-term (1+ year) human safety data are limited but the favorable short-term tolerability suggests no major concerns. Avoid standalone supplementation during pregnancy and lactation due to absence of human safety data. Avoid in advanced kidney disease due to renal excretion dependence.
What is the best PQQ product?
BioPQQ (disodium salt, Mitsubishi Gas Chemical) is the original patented form used in most human trials and has the most extensive quality and safety data. MGCPQQ is a newer Mitsubishi form with comparable specifications. Reputable brands using BioPQQ or MGCPQQ include Jarrow Formulas, Life Extension, Thorne, Designs for Health, and many others. Third-party testing (USP, NSF, ConsumerLab) has identified PQQ products with substantially less PQQ than labeled, particularly among ultra-low-cost products. PQQ is expensive to produce, and products priced at $10/month or less are unlikely to contain authentic PQQ at labeled concentrations. Always verify certificate of analysis and prefer established brands with third-party certification.
Should PQQ be taken with CoQ10?
Yes, this is the most common and most mechanistically sensible pairing. PQQ activates mitochondrial biogenesis (new mitochondria) while CoQ10 supports electron transport chain function in existing mitochondria. Nakano 2012 combined analysis showed additive cognitive benefit. Typical doses: CoQ10 (ubiquinol preferred in aging adults) 100-200 mg/day plus PQQ 10-20 mg/day. This combination is widely marketed and has the best supportive evidence among PQQ stacking combinations. Budget-conscious users should prioritize CoQ10 (more evidence, often less expensive) and add PQQ as a secondary intervention if budget allows.
Does PQQ help with fatigue?
Some users report subjective energy improvement with PQQ 10-20 mg/day, and this is consistent with the proposed mitochondrial biogenesis mechanism. However, fatigue has many causes — sleep disorders, thyroid disease, anemia, depression, nutritional deficiencies — that should be evaluated and addressed before attributing fatigue to mitochondrial dysfunction and treating with PQQ. Foundational workup (CBC, iron studies, TSH, vitamin D, B12, testosterone in men, sleep evaluation) is essential. If foundational causes are addressed or ruled out, a 12-week trial of PQQ + CoQ10 + B complex + magnesium + omega-3 is reasonable. Do not use PQQ as a substitute for addressing underlying fatigue etiologies.
How quickly does PQQ work?
PQQ plasma steady state is reached within 2-3 days of daily dosing, so direct pharmacologic effects occur rapidly. However, the downstream effects claimed for PQQ supplementation — mitochondrial biogenesis, cognitive enhancement, energy improvement — require adaptation time measured in weeks to months. Nakano 2012 assessed cognitive effects at 12 weeks. Subjective energy changes have been reported by some users within 2-4 weeks, but many users require 6-8 weeks before noticing benefit. BodyHackGuide recommends committing to 8-12 weeks of consistent use before evaluating response. Do not judge efficacy in the first 2 weeks.
Is PQQ worth the cost?
PQQ costs approximately $30-60/month at typical supplementation doses (10-20 mg/day), making it one of the more expensive single-ingredient supplements. The value proposition depends on: (a) individual response (some users perceive meaningful energy or cognitive benefit, others do not); (b) the foundational interventions already in place (sleep, exercise, diet, basic supplements produce greater effects at lower cost for most users); (c) specific goals (for mitochondrial support in aging adults with cognitive concerns, the case is stronger than for young healthy adults). A defensible approach is a 12-week trial with clear benchmarks; continue if subjective benefit; discontinue if not. Many users find that a foundational mitochondrial stack (CoQ10, magnesium, B complex, creatine, omega-3) produces more noticeable effects at similar or lower total cost.
Research Tools
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
